Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cogent Biosciences stock

Own Cogent Biosciences stock in just a few minutes.

Cogent Biosciences, Inc is a biotechnology business based in the US. Cogent Biosciences shares (UMRX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Cogent Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – UMRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cogent Biosciences share price

Use our graph to track the performance of UMRX stocks over time.

Cogent Biosciences shares at a glance

Information last updated 2021-03-07.
52-week range$0.30 - $13.90
50-day moving average $11.65
200-day moving average $6.15
Wall St. target price$5.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.36

Buy Cogent Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cogent Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cogent Biosciences financials

Revenue TTM $26.5 million
Gross profit TTM $-21,210,000
Return on assets TTM -25.76%
Return on equity TTM 0%
Profit margin 0%
Book value $0.50
Market capitalisation $73.2 million

TTM: trailing 12 months

Shorting Cogent Biosciences shares

There are currently 601,505 Cogent Biosciences shares held short by investors – that's known as Cogent Biosciences's "short interest". This figure is 39.1% down from 988,432 last month.

There are a few different ways that this level of interest in shorting Cogent Biosciences shares can be evaluated.

Cogent Biosciences's "short interest ratio" (SIR)

Cogent Biosciences's "short interest ratio" (SIR) is the quantity of Cogent Biosciences shares currently shorted divided by the average quantity of Cogent Biosciences shares traded daily (recently around 707652.94117647). Cogent Biosciences's SIR currently stands at 0.85. In other words for every 100,000 Cogent Biosciences shares traded daily on the market, roughly 850 shares are currently held short.

However Cogent Biosciences's short interest can also be evaluated against the total number of Cogent Biosciences shares, or, against the total number of tradable Cogent Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cogent Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cogent Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0211% of the tradable shares (for every 100,000 tradable Cogent Biosciences shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cogent Biosciences.

Find out more about how you can short Cogent Biosciences stock.

Cogent Biosciences share dividends

We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.

Cogent Biosciences share price volatility

Over the last 12 months, Cogent Biosciences's shares have ranged in value from as little as $0.295 up to $13.9. A popular way to gauge a stock's volatility is its "beta".

UMRX.US volatility(beta: 1.31)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cogent Biosciences's is 1.3134. This would suggest that Cogent Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cogent Biosciences overview

Unum Therapeutics Inc. , a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site